J&J de­tails Phase 3 suc­cess of au­toim­mune dis­ease drug, tout­ing broad­er range than ar­genx’s Vyv­gart

John­son & John­son’s ex­per­i­men­tal au­toim­mune treat­ment low­ered the im­pact of myas­the­nia gravis on dai­ly life com­pared to place­bo in an­ti­body-pos­i­tive pa­tients in a late-stage study …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER